This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.
Read the original research
Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials.
Lancet (London, England), 403(10437), 1635-1648
Citation
Butler, Javed; Shah, Sanjiv J; Petrie, Mark C; Borlaug, Barry A; Abildstrøm, Steen Z; Davies, Melanie J; Hovingh, G Kees; Kitzman, Dalane W; Møller, Daniél Vega; Verma, Subodh; Einfeldt, Mette Nygaard; Lindegaard, Marie L; Rasmussen, Søren; Abhayaratna, Walter; Ahmed, Fozia Z; Ben-Gal, Tuvia; Chopra, Vijay; Ezekowitz, Justin A; Fu, Michael; Ito, Hiroshi; Lelonek, Małgorzata; Melenovský, Vojtěch; Merkely, Bela; Núñez, Julio; Perna, Eduardo; Schou, Morten; Senni, Michele; Sharma, Kavita; van der Meer, Peter; Von Lewinski, Dirk; Wolf, Dennis; Kosiborod, Mikhail N. (2024). Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials.. Lancet (London, England), 403(10437), 1635-1648. https://doi.org/10.1016/S0140-6736(24)00469-0